<DOC>
	<DOCNO>NCT02217930</DOCNO>
	<brief_summary>The study design determine effect induce WCK 2349 QT interval . The study conduct two part : 1 ) determine supratherapeutic dose ; 2 ) ass safety high dose single-dose administration WCK 2349 QT interval .</brief_summary>
	<brief_title>Study Evaluate Effect Of WCK 2349 QT/QTc Interval Health Volunteers</brief_title>
	<detailed_description>Part 1 study determine supratherapeutic dose use Part 2 . Part 1will enroll 8 subject 4 dose level ( 32 subject ) . Cohorts stagger appropriate safety monitor follow-up perform subject dose level . Safety monitoring base upon review AEs , ECGs clinical laboratory test result prior escalation next dose level . At first dose level , 6 subject randomly assign receive single dose WCK 2349 1800 mg 2 subject randomly assign placebo . If dose tolerated subject , safety data allows , next group initiate fashion dose 2200 mg . If dose tolerated subject , safety data allows , next group initiate fashion dose 2600 mg . If dose tolerated subject , safety data allows , next group initiate fashion dose 3000 mg. Based upon safety data , high safely tolerate dose Part 1 utilized supratherapeutic dose Part 2 .</detailed_description>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>Male female subject 18 55 year age , inclusive , body mass index ≥18 ≤33 kg/m2 . Female subject must least 2 year postmenopausal , surgically sterile , practice 2 highly effective method birth control ( determine investigator designee ; one method must barrier technique ) , pregnant lactating , negative serum pregnancy test enrol study . Male female subject must agree practice 2 highly effective method birth control ( determine investigator designee ; one method must barrier technique ) Screening 30 day last dose study drug . Stable health base clinically significant finding medical history , physical examination , clinical laboratory test result ( determined document investigator ) . Willing comply study activity procedures provide write informed consent prior study procedure . 1 . An uninterpretable abnormal screen electrocardiogram ( ECG ) indicate second thirddegree atrioventricular block , one following : QRS interval &gt; 110 millisecond ( msec ) ; QT interval correct Fridericia 's formula ( QTcF ) &gt; 430 msec ( male ) &gt; 450 msec ( female ) ; PR interval &gt; 200 msec ; heart rate ( HR ) &lt; 45 bpm ; rhythm sinus rhythm interpret investigator clinically significant . 2 . History risk factor torsades de pointes , include unexplained syncope , know long QT syndrome , heart failure , myocardial infarction , angina , clinically significant abnormal laboratory assessment include hypokalemia , hypercalcemia , hypomagnesemia . Subjects also exclude family history long QT syndrome Brugada syndrome . 3 . A sustained supine systolic blood pressure &gt; 150 mm Hg &lt; 90 mm Hg supine diastolic blood pressure &gt; 95 mm Hg &lt; 50 mm Hg Screening Checkin ( Day 1 ) . Blood pressure may retested supine position . The blood pressure abnormality consider sustain either systolic diastolic pressure value outside state limit 2 assessment , subject may randomize . 4 . A rest HR &lt; 40 beat per minute &gt; 100 beat per minute vital sign measure Screening Checkin ( Day 1 ) . 5 . Unstable cardiovascular disease , include recent myocardial infarction cardiac arrhythmia . 6 . Uncontrolled hypertension , asthma , unstable diabetes ( type I type II ) , thyroid disease , seizures , myasthenia gravis , neuromuscular disorder . 7 . Women pregnant ( plan become pregnant within next 6 month ) currently breastfeed .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>TQT</keyword>
</DOC>